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Abstract
Background: Statin therapy is considered an effective measure for the prevention of ischemic stroke. Several
recent studies have indicated that treatment with statins, prior to the onset of acute ischemic stroke, may also
substantially reduce the severity of stroke and the degree of patient disability. The purpose of the present review is
to systematically evaluate the effectiveness of statin pretreatment on functional outcome of acute ischemic stroke
and to assess potential adverse events associated with statin use.
Methods: Relevant articles on the role of statins in acute ischemic stroke were identified via MEDLINE/PubMed,
EMBASE, CENTRAL, and by manual searches of the references of identified papers. Clinical studies (most were
prospective cohort studies) assessing statin therapy for acute ischemic stroke were selected for the review. Only
two randomized controlled clinical trials met the criteria to be included in the analysis. Clinical outcome was
assessed based on the degree of disability determined with the modified Rankin Scale (mRS) and Barthel index (BI).
The National Institutes of Health Stroke Scale (NIHSS) was used to measure stroke severity. Recurrence of stroke in
patients who had suffered from a previous stroke was analyzed with and without statin therapy. Incidence and
severity of adverse reactions was reviewed. Because there were too many differences in study outcome measures,
a quantitative analysis of data was deemed inappropriate. A qualitative summary of the data was consequently
completed.
Results: Thirteen reports were systematically reviewed to evaluate the efficacy and safety of statins in the
pretreatment of acute ischemic stroke. Pretreatment with statins was found to reduce the recurrence of stroke and
to result in more favorable outcomes for patients. The beneficial effects of prior statin therapy in acute ischemic
stroke were shown to be especially profound in whites, diabetics, elderly patients with hypertension and other
vascular diseases, and in patients with ideal low density lipoprotein (LDL) levels. There were few incidences of
adverse reactions with statin pretreatment, most of which were not statistically significant.
Conclusions: Pretreatment with statins was associated with a favorable outcome in acute ischemic stroke, with
few incidences of adverse reactions.
Background
3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA)
reductase inhibitors (statins) play an important role in
the therapeutic management of coronary heart disease
(CHD) as lipid lowering agents [1-6]. Several large, ran-
domized trials have shown that lowering LDL choles-
terol with statins reduces coronary mortality and
morbidity. The Scandinavian Simvastatin Survival Study,
a randomized, double-blind, placebo-controlled trial [1]
showed that simvastatin reduced the risk of death by
30% over the median follow-up period of 5.4 years in
patients with previous myocardial infarction or stable
angina pectoris. In the Heart Protection Study [6], sim-
vastatin given daily over the course of 5 years to high-
risk individuals was demonstrated to reduce coronary
death rate by 18% compared to placebo. Statin therapy
was also shown to prevent major adverse cardiovascu-
lar events in asymptomatic subjects at high cardiovas-
c u l a rr i s k[ 2 , 5 ] .W h i l et h er o l eo fd y s l i p i d e m i ai n
coronary heart disease is clearly well established, the
effect of lowering plasma cholesterol levels on the inci-
dence of stroke has been less definitive [7]. Observa-
tional cohort studies showed no clear relationship
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of individual data from 61 prospective studies that
included a total of 900,000 adults without previous dis-
ease did not find a positive and independent associa-
tion of cholesterol with stroke mortality [8]. However,
a meta-analysis of 90,000 patients in previous rando-
mized statin trials showed that the reduction in the
risk of stroke was related to the extent to which LDL
cholesterol levels were lowered [9]. Recent interven-
tional trials with cholesterol-lowering statins taken for
several years show significant decreases in stroke inci-
dence, with relative risk reductions ranging from 20%
to 30% [10-12]. Even in the absence of concurrent
CHD, the vast majority of patients with previous
ischemic stroke may benefit significantly from long-
term statin therapy [13].
Studies have also indicated that patients receiving sta-
tin therapy before the incidence of stroke suffer less
severe strokes and have better clinical outcomes.
Although various reports [14-21] and literature reviews
[ 7 ]h a v es u g g e s t e dt h eb e n e f i c i a lr o l eo fp r e t r e a t m e n t
with statin therapy, a systematic review of recent clinical
studies is required to evaluate both efficacy and safety of
this treatment.
Methods
The current analysis systematically reviews the efficacy
and safety of statins in the pretreatment of acute ischemic
stroke, based on previously published research papers.
Searching for studies
In April 2009, PubMed/Medline, EMBASE, and the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) were searched comprehensively using different
combinations of the following MeSH and free text
terms: acute ischemic stroke, statins, HMG-CoA reduc-
tase inhibitors, atorvastatin, simvastatin, pravastatin, flu-
vastatin, lovastatin, rosuvastatin. Additional studies were
identified via the manual searching of references of
identified papers. Unpublished data were not sought
and abstracts, letters, case reports, and review articles
were excluded. (See Additional file 1 for a quality of
reporting of meta-analyses (QUOROM) statement
checklist.)
Selection of studies
Clinical studies assessing statin therapy for acute
ischemic stroke were selected for the review. Animal
studies, studies that did not yield any findings specifi-
cally related to ischemic stroke, and studies comparing
two different statins without a placebo or treatment
control were excluded. Clinical response was defined in
terms of the modified Rankin Scale (mRS) and the
Barthel Index (BI) which measure patient disability, and
the National Institutes of Health Stroke Scale (NIHSS)
was used to assess severity of stroke.
The BI evaluates independence in activities of daily
living and ranges from severe dependence (score > 40)
and assisted independence (score < 60) to a score of 100
which reflects no disability. The mRS assesses functional
outcome with scores ranging from 0 to 6 (0, no symp-
toms; 1, no significant disability despite symptoms and
able to carry out all usual duties and activities; 2, slight
disability, unable to carry out all previous activities but
able to look after own affairs without assistance; 3, mod-
erate disability requiring some help but able to walk
without assistance; 4, moderate severe disability, unable
to walk without assistance, and unable to attend to
own bodily needs without assistance; 5, severe disabil-
ity; bedridden, incontinent, and requiring constant
nursing care and attention; and 6, death). The NIHSS
measures stroke severity on a scale of 1-42 with a
score of 0 for no stroke, 1-4 = minor stroke, 5-15 =
moderate stroke, 15-20 = moderate/severe stroke and
21-42 = severe stroke.
An additional outcome measure was the incidence and
severity of adverse events.
Data abstraction
The authors independently extracted the data, and any
disagreements were resolved by consensus. The extracted
information from each study included: study type, study
objective, sample size, controls, type and amount of stain
used, study duration, outcome measures, and reported
adverse events.
Analysis
There were too many differences in outcome measures
of studies so a quantitative analysis of data was deemed
inappropriate. A qualitative summary of the data was
consequently completed.
Results
Study characteristics
Electronic searches found 26 reports that were poten-
tially relevant to the present review. 5 articles were
excluded because they discussed animal studies. Six
reports were excluded for not yielding any findings speci-
fically related to ischemic stroke. Two studies compared
two different statins without a placebo or treatment
control and were excluded. (See Figure 1 for a flow
diagram of included studies.). Three reports analyzed
different patient subtypes or different aspects of the
same clinical trial.
A total of 13 studies were reviewed. Eight studies (see
Tables 1 and 2) assessed the efficacy of statin therapy
[14-21] and 5 articles (Table 3) evaluated the safety of
statin therapy [12,22-24]. One report [21] analyzed both
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week to 6 years. Outcome measures included odds ratio
(OR), mRS scores, BI and NIHSS scores.
Clinical responses observed
As reported in Martí-Fàbregas (2004), statins may
improve long-term outcome when administered before
the onset of cerebral ischemia [14]. This prospective
study showed that patients who were already being trea-
ted with statins at the time of stroke were less affected
neurologically and had a better long-term functional out-
come than patients who were not receiving statins.
Favorable outcomes, defined as a mRS of 0 to 1 and a BI
score of 95 to 100 at 3 months were more frequent in the
statin group (80% vs. 61.3%, P = 0.059 with the mRS;
76.7% versus 51.8%, P = 0.015 with the BI). Mortality was
not significantly different in the two groups (3.4% in the
statin group and 6.6% in the nonstatin group).
An observational study of 436 patients by Yoon et al
(2004) reported that 51% of patients taking statins
before hospital admission for stroke had a good out-
come at discharge (defined as a Rankin score < 2) com-
pared to 38% of patients not taking statins (P = 0.03).
The mortality rate from acute ischemic stroke was 6/84
(7.1%) in patients with statin pretreatment, compared to
30/309 (9.7%) in patients without statin pretreatment
[15]. Greisenegger (2004) performed a cross-sectional
study of 1691 stroke patients and evaluated clinical Figure 1 Flow diagram of included studies.
Table 1 Clinical outcome in patients taking statins before the incident of stroke
Study NIHSS mRS Other clinical measures (BI, imaging)
Martí-Fàbregas 2004
[14]
Not significantly different mRS of 0-1 in 80% in statin
group vs. 61.3% in non-statin
group, P = 0.059
BI of 95-100 in 76.7% in statin group vs. 51.8% in
non-statin group, P = 0.015
Yoon 2004 [15] N/A 51% in statin group vs. 38% in
non-statin group had mRS < 2;
P = 0.03
Greisenegger 2004 [16] N/A 6% in statin group vs. 14% in
non statin group had a mRS of
5o r6
Moonis 2005 [17] Significantly more patients had
NIHSS ≤ 2 in statin group vs.
non-statin, P = 0.008
Significantly more patients had
mRS ≤ 2 in statin group vs.
non-statin, P = 0.045
Reeves 2008 [18] N/A 35.9% in statin group had mRS ≥
4 vs. 44.3% in non-statin group
Nicholas 2008 [19] N/A N/A Statin pretreatment in patients with diabetes
resulted in a smaller than median infarct volume
after ischemic stroke (P = 0.01).
Stead 2009 [20] Not significantly different Patients on statins were
significantly more likely to have a
mRS ≤ 2
Goldstein 2009 [21] Not significantly different a trend toward reduced disability
with stains based on mRS
(P = 0.0647)
BI, Barthel Index; mRS, modified Rankin Scale; N/A, not available; NIHSS, National Institutes of Health Stroke Scale.
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ischemic stroke (defined as a mRS of 5 or 6) was less
frequent in patients receiving statin treatment before the
event (6% vs. 14%, OR = 0.37, 95% CI = 0.19-0.74, P =
0.004). Statin pretreatment seems to be associated with
reduced stroke-induced disability, most notably in
patients with diabetes [16].
Moonis (2005) evaluated the potential effects of statins
initiated at least 4 weeks before acute ischemic stroke.
Multivariate logistic regression analysis demonstrated
that post-stroke statins were associated with a significant
probability of a favorable outcome at 12 weeks [NIHSS
(P = 0.002; OR = 1.92; CI = 1.27-2.91) and mRS (P =
0.033; OR = 1.57; CI = 1.04-2.38)], whereas pre-stroke
statins demonstrated a trend toward significance [17].
Reeves (2008) found that pretreatment with statins
was associated with lower odds of poor outcome (OR =
0.74, 95% CI 0.52-1.02) and also reported a significant
interaction (P < 0.01) between statin use and race. In
whites, statins were associated with statistically signifi-
cantly lower odds of poor outcome, defined as a
modified Rankin score ≥ 4 at discharge (OR = 0.61, 95%
CI = 0.42-0.86). In blacks, statins were associated with a
non-statistically significant increase in poor outcome
(OR = 1.82, 95% CI = 0.98-3.39) [18]. In-hospital mor-
tality was found to be lower among the statin users:
2.3% (n = 7) of the 309 subjects on statins before admis-
sion died in-hospital, compared to 6.6% (n = 69) of the
1051 subjects not on statins.
Nicholas (2008) conducted a retrospective cohort analy-
sis of stroke patients to examine infarct size with magnetic
resonance diffusion-weighted imaging. They reported a
smaller than median infarct volume after ischemic stroke
in diabetic patients who were taking statins at onset of
ischemic stroke [19].
In a prospective cohort study, Stead (2009) evaluated
508 patients presenting with an acute ischemic stroke
and measured their lipid profiles during a 22-month
Table 2 Study design and odds ratio
Study Study design # of
patients
Follow up
period
OR, 95% CI, P value Measures
Martí-Fàbregas 2004 [14] cohort 167 3 months OR = 5.55; 95% CI = 1.42-17.8;
P = 0.012
Favorable outcome (NIHSS,
mRS ≤ 2, BI)
Yoon 2004 [15] observational 436 2 years OR = 2.9; 95% CI = 1.2-6.7,
P = 0.03
Favorable outcome (mRS ≤ 2)
Greisenegger 2004 [16] cohort 1691 1 week OR = 0.37; 95% CI = 0.19-0.74;
P = 0.004
Poor stroke outcome (mRS of
5o r6 )
Moonis 2005 [17] cohort 852 12 weeks OR = 1.57; 95% CI = 1.04-2.38;
P = 0.033
Favorable outcome (mRS ≤ 2)
Reeves 2008 [18] cohort 1360 6 months OR 0.74, 95% CI = 0.52-1.02 Poor stroke outcome
(mRS ≥ 4 at discharge)
Stead 2009 [20] cohort 508 22 months OR = 1.91; 95% CI = 1.05-3.47 Favorable outcome (NIHSS,
mRS ≤ 2)
Goldstein 2009 [21] Exploratory analysis of
SPARCL trial data
576 3 months N/A Favorable outcome (NIHSS,
mRS)
mRS, modified Rankin Scale; N/A, not available; NIHSS, National Institutes of Health Stroke Scale. OR, Odds Ratio; CI, Confidence Interval.
Table 3 Adverse events in studies testing statin pretreatment
Study Study design # of
patients
Follow up
period
Findings
PROSPER Study
(Shepherd 2002 [22])
Randomized controlled trial 8804 3.2 years 25% increased incidence of cancers (P = 0.020) in patients receiving
statin compared to placebo. Meta-analysis of previous pravastatin and
other statin trials showed no overall increase in cancer risk.
CTT study (Baigent
2005 [12])
Prospective meta-analysis of
14 randomized trials
90 056 5 years No evidence of increased the incidence of cancer by statins (OR =
1.00, 95% CI 0.95-1.06; P = 0.9). Excess risk for rhabdomyolysis with
statin not significant.
SPARCL Trial
(Amarenco 2006 [13],
Double-blind, randomized, 4731 Median
4.9 years
Hemorrhagic stroke was more frequent in statin group, in those with
a hemorrhagic stroke as an entry event. Total and LDL cholesterol
levels did not affect the risk of hemorrhagic stroke.
Goldstein 2008 [23] Multicenter trial
Meier 2009 [24] Prospective cohort study 311 3 months More patients with ICH were on statins (30% vs. 15%, P = 0.005).
Frequency of ICH is associated with previous statin use (OR = 3.1;
95% CI = 1.53-6.39; P = 0.004).
ICH, intracranial hemorrhage; LDL, Low-Density-Lipoprotein; OR, Odds Ratio; CI, Confidence Interval.
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dL and receiving statins (n = 100) were significantly
more likely to have a good functional outcome, defined
as modified Rankin scale score of 0-2, when compared
with those not on the medication (OR = 1.91; 95% CI =
1.05-3.47) [20].
T h eS t r o k eP r e v e n t i o nb yA g g r e s s i v eR e d u c t i o ni n
Cholesterol Levels (SPARCL) study [13] was the first
randomized controlled trial specifically designed to
investigate the effect of the reduction in cholesterol
levels with atorvastatin in secondary stroke prevention.
This trial included a total of 4,731 patients who had a
stroke or transient ischemic attack (TIA) 1-6 months
before study entry. The patients were randomized to
atorvastatin or placebo, with a mean follow-up period of
4.9 years. The results showed a 16% relative risk reduc-
tion of recurrent stroke with atorvastatin [13]. Goldstein
(2009) performed a secondary analysis of data from the
SPARCL study, focusing on the severity and functional
outcome of recurrent stroke [21]. There was a trend
toward lower disability with treatment based on the
mRS score (P = 0.0647) - 218 patients in the atorvasta-
tin group had an ischemic stroke versus 274 in the pla-
cebo group - but no differencei ns t r o k es e v e r i t yb a s e d
on the NIHSS was found.
Overall, the studies reviewed indicated that statin pre-
treatment results in favorable outcome in stroke
patients; however a quantitative analysis of this effect
was not feasible because the outcome measures in the
studies listed were too variable. An attempt at compar-
ing the quality of the individual studies was made by
plotting the OR and 95% CI for reduced disability
(mRS) from the studies for which these values were
available (Figure 2).
Adverse reactions observed
Four studies assessed adverse events in patients on sta-
tin therapy before the stroke onset (Table 3). In the
PROSPER (PROspective Study of Pravastatin in the
Elderly at Risk) study, a randomized controlled trial,
there was a 25% increased incidence of cancer (P =
0.020) in patients receiving pravastatin for 3 years com-
pared to placebo [22]. However, a meta-analysis of can-
cer rates in previous pravastatin and other statin trials
showed no overall increase in cancer risk. [23]. The
CTT study (Cholesterol Treatment Trialists’ Collabora-
tion), a prospective meta-analysis of data from 90,056
individuals in 14 randomized trials of statins [12], found
no evidence that statins increased the overall incidence
of cancer. The 5-year excess risk for rhabdomyolysis
with statin was small and not significant. A significant
increase of brain hemorrhages in atorvastatin-treated
patients was observed in the SPARCL trial in which sec-
ondary stroke prevention was analyzed, whereas total
and LDL cholesterol levels did not affect the risk of
hemorrhagic stroke [13,23]. The risk for brain hemor-
rhage was also analyzed by Meier (2009) who looked at
311 patients who received intra-arterial thrombolysis
[24]. They showed that the overall frequency of intracra-
nial hemorrhage was higher in patients receiving statin
therapy before their stroke compared to those without
(34.5% vs. 17.6%, P = 0.005). Clinical outcome after 3
months did not differ significantly between the statin
and non-statin groups.
Discussion
The aim of this systemic review was to determine the
effect of statin pretreatment on the severity of acute
ischemic stroke and on the degree of post-stroke
functional disability. Additionally, the safety of statin
pretreatment was evaluated. The evidence from cross-
sectional, observational and prospective studies as well
as randomized placebo-controlled trials was promising,
yielding significant findings that suggest that prior statin
therapy is associated with favorable outcome and few
adverse events.
Statins inhibit HMG-CoA reductase, an enzyme that
converts HMG-CoA to mevalonate, a precursor of cho-
lesterol [25]. In acute ischemic stroke, the cholesterol
lowering potential of statins comes into action. How-
ever, the link between serum cholesterol level and the
incidence of stroke remains to be fully established. Sev-
eral reports [26-28] indicate that in comparison with
patients with normal cholesterol levels, patients with
high cholesterol levels had a lower risk of death and a
lower risk of poor functional outcome. It is becoming
clear that the clinical action of many cholesterol-
l o w e r i n gd r u g si st h er e s u l to fpleiotropic effects rather
than simply a reduction in cholesterol. These pleiotropic
Figure 2 Odds Ratio for disability based on mRS scores.N o t e
that Greisenegger 2004 supplied data for the reduced frequency of
patients with a higher mRS (enhanced disability) and Reeves 2008
analyzed patients with a mRS ≥4, whereas the other studies defined
reduced disability as a mRS of ≤2.
Lakhan et al. International Archives of Medicine 2010, 3:22
http://www.intarchmed.com/content/3/1/22
Page 5 of 7effects include attenuation of vascular inflammation,
improved endothelial cell function, stabilization of ather-
osclerotic plaque, decreased vascular smooth muscle cell
migration and proliferation, and inhibition of platelet
aggregation [28,29]. For example, simvastatin, when
administered within 24 hours of the acute ischemic
stroke onset, can also inhibit the increase in serum
TNF-a, a mediator of inflammation [30] which may
have significant clinical impact. There is also evidence,
most prominently from the JUPITER trial [31] that sta-
tins lower the levels of C-reactive protein (CRP) and
may reduce the risk of coronary events independently of
the effect of statins on lipid levels. Because increased
levels of CRP have been associated with arterial-wall
inflammation, statins can prevent ischemia by both inhi-
biting deposition of lipids and decreasing inflammation.
T h es t r o k ep r o t e c t i o na c t i v i t yo fs t a t i n sm a ya l s ob e
due to the fact that statins improve cerebrovascular
reactivity [32].
In acute ischemic stroke, the occurrence and size of
cerebral infarction is influenced by the collateral circula-
tion in the brain [33]. Pre-stroke statin use may improve
the pretreatment angiographic collateral grade among
acute ischemic stroke patients presenting with occlusion
of a major cerebral artery. In the cardiovascular system,
prior statin treatment enhances the collateralization of
coronary arteries and thereby improves the outcome of
coronary artery disease. In the cerebrovascular system,
statin associated enhancement of collateralization of cer-
ebral arteries leads to a better outcome in acute
ischemic stroke. Pretreatment with atorvastatin was
associated with better outcome after an ischemic stroke
mainly in atherothrombotic and lacunar infarctions,
with no significant effect on other stroke subtypes [34].
While pretreatment with statins was associated with
better stroke outcomes in whites, there was no evidence
of a beneficial effect of statins in black patients [18]. In
patients with diabetes, prior statin therapy for acute
ischemic stroke was found to be particularly beneficial
[16]. The lipid lowering as well as anti-inflammatory
effects of statins may have a role in controlling diabetes,
which in itself is a risk factor for acute ischemic stroke.
Statin withdrawal, in patients receiving pretreatment
with statins for ischemic stroke, was associated at 90
days with increased risk of death or dependency from
acute ischemic stroke. This suggests that statin therapy
should be continued during the acute phase of ischemic
stroke [35].
Few incidences of adverse reactions were reported in
clinical studies. The risk of cancer in patients taking statins
was evaluated but was found not to be significantly
increased [12,22]. Although statins appear to be beneficial
f o ri s c h e m i cs t r o k e ,t h er i s kf o rh e m o r r h a g i cs t r o k ew a s
increased in patients pre-treated with statins [13,23,24],
particularly those with a prior hemorrhagic stroke, male
sex, advanced age, and stage 2 hypertension. Therefore,
the benefits of statins in preventing ischemic stroke and
cardiovascular events have to be weighed carefully against
the possibility that they may increase the risk for hemor-
rhagic stroke.
Prior statin use by patients admitted to hospitals with
acute ischemic stroke is increasingly common [15]. This
trend can be expected to continue due to continuing
reports of the beneficial effects of statins on stroke pre-
vention in elderly individuals with hypertension and vas-
cular disease [36,37]. The American Heart Association/
American Stroke Association now recommends the
administration of statin therapy with intensive lipid-
lowering effects in patients with atherosclerotic ischemic
stroke or TIA and without known coronary heart dis-
ease to reduce the risk of stroke and cardiovascular
events [38,39]
This systematic review concludes that administration of
statin treatment before acute ischemic stroke is clinically
justified, particularly in whites, diabetics and patients
with ideal LDL levels. However, more randomized dou-
ble-blind placebo-controlled trials are required to defini-
tively evaluate the safety of statin pretreatment, and
to compare the efficacy and dosage of individual
statin types.
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